ClinicalTrials.gg
Not yet recruitingNCT07332130Updated Jan 12, 2026

Spinal Analgesia in Labour Pain

A Phase 1 interventional study of injecting dexmedetomidine and injecting mixture of bupivacaine fentanyl in Labour Analgesia, sponsored by Minia University Hospital. Not yet recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Minia University Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

To evaluate the efficacy and safety of dexmedetomidine as an adjuvant to bupivacain and fentanyl in spinal Analgesia to decreases pain during normal labour

Read the detailed description

Effect of adding dexmedetomidine to bupivacain fentanyl mixture in spinal analgesia for normal labour

02

Conditions studied

  • Labour Analgesia
03

In context

Lead sponsor

Minia University Hospital is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age of patint is between 18 and 40 years. gestational age of fetus is more than 37 weeks. singleton viable fetus and cephalic presentation. spontaneous labor with cervix dilation more than 5cm.

Exclusion criteria

Exclusion Criteria:

Drug allergy. Blood Disease. Infection at site of injection. patient takes anticoagulants. patient has pre-eclampsia ,cardiac disease ( III-IV) or diabetes mellitus type I prior to the pregnancy patients refuse

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    DEX

    Participants receive intrathecaliy hyperbaric bupivacaine 2.5 mg (0.5 mL) combined with dexmedetomidine 2.5 µg and fentanyl 25 µg, diluted to a total volume of 2.5 mL. The solution will be administered as a single spinal injection under aseptic conditions.

    Drug: injecting dexmedetomidine

  • Active comparator
    CONTROLLED

    Participants will receive intrathecaliy hyperbaric bupivacaine 2.5 mg (0.5 mL) combined with fentanyl 25 µg, diluted to a total volume of 2.5 mL. The solution will be administered as a single spinal injection under aseptic conditions.

    Drug: injecting mixture of bupivacaine fentanyl

Interventions

  • Druginjecting dexmedetomidine

    injecting dexmedetomidine intrathecally during labour pain

  • Druginjecting mixture of bupivacaine fentanyl

    injecting mixture of bupivacaine fentanyl intrathecally

06

What researchers measure

Primary outcomes

  1. changes in numeric pain intensity score ( NPSI) maximum 10 minimum 0

    evaluate the safety and effecacy of dexmetomidine for labour pain by numeric pain intensity score maximum 10 ( sever pain ), minimum 0 ( no pain )

    Time frame: baseline

  2. duration of sensory blockade

    change in numeric pain intensity score ( NPIS )

    Time frame: 5 minutes after injection of analgesic agents till normal delivery done

  3. changes in numeric pain intensity score ( NPIS )

    Scores range from 0-10 points, maximum ( 10 ) means sever pain, minimum ( 0 ) means no pain

    Time frame: 5 minutes, 10 minutes, 15 minutes, 30 minutes and 45 minintes after injection of analgesic agents

07

Study locations

1 site
  • Minya
    Minya, 61915, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — all collected IPD,

Supporting information: Study protocol

Time frame: december 2025 - december 2026

Access criteria: labour analgesia

Data sharing details ↗ · clinicaltrials.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Jan 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Jan 12, 2026
StartEst.
Dec 24, 2025
Primary completionEst.
Jan 10, 2026
CompletionEst.
Mar 2, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07332130
Lead sponsor
Minia University Hospital
Responsible party
Mohamed Ragab Mohamed (residant, Minia University Hospital) — Principal investigator
First posted
Jan 12, 2026
Start date
Dec 24, 2025 (estimated)
Primary completion
Jan 10, 2026 (estimated)
Completion
Mar 2, 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Mohamed Ragab, Master
Contact
mohamedragab2209@gmail.com
086-01001737436
Mohamed Ragab, master
principal investigator · Minia University Hospitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion